Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs), will present new data from its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback